Objective: To examine associations between antidepressant use and health care utilization in young adults beginning maintenance hemodialysis (HD) therapy. all) than the untreated group. Overall, 68 (52.3%) had 1 or more hospitalizations and 33 (25.4%) had 1 or more ED visits in the first year. The risk of hospitalization during the first year was higher in the antidepressant use group (hazard ratio, 2.35; 95% CI, 1.39-3.96; P¼.001), which persisted after adjustment for diabetes, coronary artery disease, and heart failure (hazard ratio, 1.94; 95% CI, 1.22-3.10; P¼.006). Emergency department visit rates were similar between the groups. Conclusion: Depression and antidepressant use for mood indication are common in young adult incident patients initiating HD and and are associated with higher hospitalization rates during the first year. Further research should determine whether antidepressants are a marker for other comorbidities or whether treated depression affects the increased health care use in these individuals.
I
n 2014, approximately 120,000 individuals developed end-stage renal disease in the United States. 1 Among this cohort was a small minority (13, 630 ; 11%) of young adults aged 22 to 44 years who faced especially unique challenges because of this new reality. The first several months after dialysis initiation represents a difficult transition time marked by hospitalizations, emergency department (ED) visits, hospital readmissions, and premature deaths. [2] [3] [4] Young adult patients may be particularly susceptible during this time, given the recent transition from pediatric to adult medical care, 5 abrupt alteration in health and/or social status, potential onset of major mental disorders in late teen/early adult years, 6, 7 and recent completion of neuromaturation during their early to mid-20s. [8] [9] [10] Hence, despite having fewer medical comorbidities than older patients initiating dialysis, young adults had high rates of hospitalizations 2, 3 and an exceptionally high 30-day readmission rate (>40%). [1] [2] [3] The reason for increased health care use in young adults initiating maintenance hemodialysis (HD) is unclear. It is known that (1) psychosocial factors affect resource use as patients transition from pediatric to adult care teams 11, 12 and (2) depression, common in patients initiating dialysis, [13] [14] [15] may be associated with increased morbidity. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Hence, given that dialysis dependency is a risk factor for depression and/or antidepressant use, we hypothesized that antidepressant use for depression may be a marker for the increased psychosocial distress that contributes to increased health care utilization in this otherwise "healthy" cohort of younger patients with HD.
In this study, we examined the association between antidepressant use, hospitalizations, and ED visits within the first year of HD initiation in young incident patients initiating HD. Identifying markers of psychosocial burden, such as depression, anxiety, and antidepressant pharmacotherapy, in incident patients may allow the development of interventions to reduce health care use and costs while improving quality of life.
PATIENTS AND METHODS

Cohort Selection
The Mayo Clinic Health System (MCHS) provides health care to nearly 400,000 residents in southeast Minnesota, northern Iowa, and southwest Wisconsin. The Mayo Clinic Dialysis Services (MCDS) provides all inpatient and outpatient HD in the MCHS. The study included all young adult patients (age, 18-44 years at initiation; n¼161) initiating HD from January 1, 2001, through December 31, 2013, with Minnesota Research Authorization. Patients were excluded for lack of in-center maintenance dialysis therapy at MCDS beyond 30 days (n¼31), leaving a final study cohort of 130 patients. The Mayo Clinic Institutional Review Board approved this study.
Data Collection
Patient demographic characteristics, comorbidities, and cause of kidney failure were obtained by electronic medical record review. [25] [26] [27] Psychiatric history, substance use history, and patient-reported suicide attempts were obtained by review of clinical notes, patientcompleted medical history forms, and outside medical records from institutions beyond MCHS. Records were also reviewed for physician diagnoses of depressive disorders using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) terms of depression and depressive disorder with any modifiers, as well as dysthymic disorder. The same method was implemented for diagnoses of other psychiatric conditions. Psychiatric diagnoses contained in DSM-IV, except substance abuse disorders, were categorized into anxiety, bipolar, psychotic, adjustment, personality, and other disorders. Substance use history included tobacco use, alcohol abuse/dependence, and illicit substance abuse/dependence within 6 months before dialysis initiation. Illicit substances were classified as cannabis, heroin/ cocaine, methamphetamines, nonopioid prescription pills, opioid (inappropriate use or not taken as prescribed), and other substances (including "street drugs" or psilocybin mushrooms). Alcohol abuse/dependence was based on DSM-IV criteria or clinical documentation of "excessive" alcohol use, "abuse," or previous involvement in an alcohol rehabilitation program.
Antidepressant Therapy
Antidepressant medication use was chosen as the marker for depression, as it reflects a depressive disorder of sufficient severity to justify pharmacotherapy. An electronic medical record review of medication lists and clinical notes was used to identify antidepressant pharmacotherapy at dialysis initiation. Antidepressant therapy use at HD initiation was defined as (1) active use of antidepressant medication and confirmed by (2) documented indication of treatment of a depressive disorder. Antidepressants taken for a nondepressive disorder were recorded, but patients were not classified in the antidepressant use group. Pharmacotherapy for depression was categorized as selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, tricyclic antidepressant, bupropion, or other (such as monoamine oxidase inhibitors or neuroleptic agents with a primary indication of mood disorder treatment). The untreated group at baseline was also followed for identification of antidepressant therapy initiation during the study period.
Outcomes
The 2 primary outcomes included hospitalizations and ED visits (without subsequent hospitalization) within the first year of HD initiation. Patients were followed for 1 year, starting on the date of HD initiation and censored at death, voluntary withdrawal of HD before death, kidney transplant, renal function recovery allowing HD discontinuation, transfer to a non-MCDS facility for HD continuation, or transition to home dialysis or peritoneal dialysis therapy. The primary cause of hospitalizations and ED visits were categorized as cardiac, infection, gastrointestinal, dialysis vascular access, vascular (noncardiac), neurological, trauma, endocrine, pulmonary, malignancy/hematologic, pain, psychiatric, and other. Planned hospitalizations for procedures or events such as chemotherapy, obstetric care or delivery, and rehabilitation were excluded from analyses.
Statistical Analyses
Continuous variables were reported as mean AE SD and median with interquartile range. Categorical variables were expressed as count and percentage. Categorical patient characteristics and rates were compared between antidepressant-treated and nontreated groups by using the chi-square test of independence and Fisher exact test for expected frequencies of less than 5. Age was compared using a 2-sample t test, and time receiving HD was compared using the Wilcoxon rank-sum test because of its skewed distribution. The mean length of hospital stay was assessed using generalized estimating equations with the log link function.
We assessed differences in time to first hospitalization along with hospitalization and ED visit rates between antidepressant and nontreated groups. Confidence intervals at the 95% level were calculated for rates by using the Poisson exact method. Kaplan-Meier plots were used to compare time to first hospitalization, and failure curves were compared using the log-rank test. Rates of hospitalizations and ED visits were compared using the Andersen-Gill model to allow for multiple hospitalizations or ED visits per patient. The model controlled for diabetes, coronary artery disease, and heart failure. The proportional hazards assumption was assessed by including an interaction between antidepressant use and logarithm of time as well as by plotting the Schoenfeld residuals.
To determine the feasibility of using the diagnosis of a depressive disorder as the marker, in comparison to antidepressant pharmacotherapy, these analyses were repeated.
We examined the relationship between depression, defined as a diagnosis of a depressive disorder at dialysis initiation (n¼47 [36.2% of the total cohort]), and health care utilization. A P value of less than .05 was considered statistically significant. Analyses were performed using SAS 9.4 (SAS Institute, Inc).
RESULTS
Study Participants
From January 1, 2001, through December 31, 2013, 130 patients aged 18 to 44 years initiated maintenance HD therapy and continued receiving HD for a minimum of 30 days in the MCDS. Baseline demographic characteristics, comorbid conditions, cause of kidney failure, and details surrounding dialysis initiation and follow-up are summarized in Table 1 Table 2 . Overall, tobacco and/or alcohol abuse was more common (62; 47.7%) than any illicit substance use. Cannabis was the most commonly used illicit substance (20; 15.4%). Other than depression (47; 36.2%), the most common comorbid psychiatric conditions were adjustment disorders (14; 10.8%) and anxiety disorders (13; 10.0%). At least 1 previous suicide attempt was found in 9 patients (6.9%). Although not receiving antidepressants at the time of dialysis initiation, 19 of 102 (18.6%) had a history of a depressive disorder. Of these, 10 (9.8%) began antidepressant medication during the 1-year follow-up period. Of the 28 patients receiving antidepressants at dialysis initiation, 21 (75%) were receiving selective serotonin reuptake inhibitor, 1 (3.6%) receiving a serotoninnorepinephrine reuptake inhibitor, 4 (14.3%) receiving a tricyclic antidepressant, 4 (14.3%) receiving a bupropion, and 1 (3.6%) receiving another medication (trazodone). Four patients (14.3%) were receiving more than 1 antidepressant.
Follow-Up
The overall median study follow-up period was 307 days (range, 32-366 days). The antidepressant use group had a median study follow-up period of 365 days (range, 32-366 days), whereas the untreated group had a median study follow-up period of 238 days (range, 32-366 days though this was not statistically significant (median, 55 days vs 213 days; log-rank, P¼.09) (Figure 1 ). Andersen-Gill models were used to calculate hazard ratios (HRs) for multiple hospitalizations per patient. The proportional hazards assumption was satisfied for the hospitalization outcome. No value is reported for the 75th percentile because the Kaplan-Meier estimator for these data never reaches a failure probability of 0.75 or greater. c P¼.91 is the resultant P value obtained from a model using generalized estimating equations with the log link function to compare the mean length of hospital stay between the antidepressant and untreated groups.
Emergency Department Visits. Emergency department visits without subsequent hospitalization were common (33; 25.4%) (Table 4) . However, among patients with at least 1 ED visit (n¼33) during the 1-year follow-up period, most (n¼22 [66%]) had only 1 ED visit. There was no difference in time to first ED visit between antidepressant and untreated groups (log-rank, P¼.65). There was no difference in ED visits between depression groups in the first 4 months (HR, 0.86; 95% CI, 0.34-2.20; P¼.75), and there was no difference in ED visits between depression groups after 4 months (HR, 2.58; 95% CI, 0.77-8.70, P¼.12). In addition, adjusted models did not exhibit statistically significant differences. Adjusted models yielded similar results.
Individualized Events in the Antidepressant Use Group. We created mosaic plots to graphically illustrate follow-up time combined with individual hospitalizations (Figure 3, A) and ED visits (Figure 3, B) for each patient in the antidepressant use group during the first year. As shown, few patients experienced multiple events whereas some were event-free during the 1-year follow-up period. Hospitalizations and ED visits included cardiac, endocrine, gastrointestinal, 
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and infectious etiologies. In a sensitivity analysis, 1 patient with 13 hospitalizations was excluded from the study cohort and hospitalizations were reanalyzed using Andersen-Gill models. The results were similar to the main findings and indicated an association between antidepressant use and hospitalizations (unadjusted HR, 1.98; 95% CI, 1.21-3.25; P¼.007) even after adjustment for diabetes, coronary artery disease, and heart failure (HR, 1.79; 95% CI, 1.09-2.92; P¼.02).
"Diagnosis of Depression" as a Marker for Health Care Use. Further sensitivity analyses examined the relationship between health care utilization and depression (defined as a diagnosis of depressive disorder before dialysis initiation; n¼47 [36.2% of the total cohort]). According to this definition of depression, individuals with depression had a higher risk of hospitalization (HR, 1.80; 95% CI, 1.10-2.95; P¼.02) during the 1-year follow-up period. However, this association was attenuated after adjustment for diabetes, coronary artery disease, and heart failure (HR, 1.51; 95% CI, 0.96-2.39; P¼.08). There was no difference in ED visits between those with depression and those without (unadjusted HR, 1.96; 95% CI, 0.98-3.91; P¼.06 and adjusted HR, 1.50; 95% CI, 0.74-3.04; P¼.30).
DISCUSSION
We observed that antidepressant use for depression is common (28; 21.5%) and a diagnosis of depression, whether treated or not, is highly prevalent (47; 36.2%) in young adult patients at hemodialysis initiation. Moreover, antidepressant use at dialysis initiation is independently associated with increased health care utilization in the first year after dialysis initiation. Therefore, despite receiving treatment for depressive disorders, young incident patients initiating HD treated with antidepressant therapy represent a high-risk group and may benefit from interventions to reduce health care utilization and costs.
Previous studies conducted nearly 10 to 15 years ago focused on depression and hospitalization in the general population initiating dialysis. 14, 15, 17, 19, 24, 28 Perhaps the largest studies were conducted by Lopes and coworkers 14, 15 using Dialysis Outcomes and Practice Patterns Study data. In their international study, Lopes et al 14 found an adjusted risk of hospitalization of 1.11 (95% CI, 1.01-1.22; P¼.04) in depressed patients (vs nondepressed), which was similar after removing 28 found depression to be associated with an increased number of hospitalizations (adjusted rate ratio, 1.30; 95% CI, 1.11-1.52) and hospital days (adjusted rate ratio, 1.31; 95% CI, 1.04-1.66). Similarly, in our antidepressant-treated patients, the risk of hospitalization adjusted for diabetes, coronary artery disease, and heart failure was nearly 2-fold (HR, 1.94; 95% CI, 1.22-3.10; P¼.006), suggesting an independent association of depression with health care use in the first year after dialysis initiation.
The prevalence of depression and/or antidepressant use was high in our study, though comparable to that in previous reports. Watnick et al 29 identified 44% (54 of 123) of incident patients initiating dialysis with positive scores for depressive symptoms meeting the Beck Depression Inventory validated cutoff. Similarly, in a systematic review Palmer et al 13 reported the high prevalence of depressive symptoms (39.3%; 95% CI, 36.8%-42.0%) in patients initiating dialysis, though it was lower in those with interview-based depression diagnoses (22.8%; 95% CI, 18.6%-27.6%). Although our prevalence (36%) of depression is similar to that in the general population initiating dialysis, it is concerning to find such high rates of depression and/or antidepressant use in this young population initiating dialysis. Chronic conditions such as diabetes may partly explain the high prevalence of depression in this population initiating dialysis compared with the young general population. 30, 31 The odds of major depression are higher in adults and pediatric patients with diabetes and concomitant endorgan complications such as kidney failure. [32] [33] [34] [35] Although diabetes was more common in our antidepressant cohort, a test of interaction between diabetes and antidepressant use was not significant.
The burden of chronic and/or acute illness in individuals beginning maintenance HD therapy may be overwhelming, particularly in young individuals. Several studies have shown that depression is associated with reduced survival in patients initiating dialysis, whereas others have not consistently supported this notion. It is unclear whether depression is a marker for or modifier of other aspects of health. 16, [20] [21] [22] [23] [24] 36 Despite receiving pharmacotherapy, our study patients had higher rates of hospitalizations than did untreated patients. In additional analyses, we examined the association between health care use and a diagnosis of depression at baseline, which was not significant after adjustment for diabetes, coronary artery disease, and heart failure (P¼.08 for risk of hospitalization and P¼.30 for risk of ED, respectively). Therefore, it may be reasonable to use the presence of an antidepressant agent as opposed to a diagnosis of depression as a biomarker for assessing risk of health care utilization in young patients initiating HD.
Our study has several limitations. This was not a prospective study and had a relatively small sample size of incident patients over a several-year time frame during which practice patterns changed. Because young patients (age, 22-44 years) make up only 11% (n¼13,630) of the incident population with end-stage renal disease in the United States, 1 future studies may require large multicenter samples of young patients initiating dialysis. In addition, we did not examine the efficacy of or adherence to antidepressant therapy in the setting of dialysis therapy, nor did we examine the effect of psychotherapy or socioeconomic status, both barriers to access to mental health services, or family/community support, which may confound the association between depression, antidepressant use, and health care utilization. Each of these factors should be a potential area of focus for future prospective research.
CONCLUSION
A diagnosis of depression and use of antidepressant pharmacotherapy are common in young adult incident patients initiating HD. Antidepressant pharmacotherapy may represent a marker for the increased risk of hospitalization during the first year even after controlling for other comorbid medical conditions. However, prospective studies are needed to examine whether modifying depressive symptoms through antidepressant pharmacotherapy, psychotherapy, and other treatment interventions is of benefit in the reduction of health care costs and improvement in quality of life for young patients beginning dialysis.
